Company attributes
Other attributes
Redesign Science Inc is a computational chemistry company that is interested in small molecule drug discovery. The company was founded by David Rooklin and Haotian Li in 2017 in New York, New York, United States.
The company looks to stimulate protein targets at the atomic level to reveal drug opportunities that fall outside the scope of alternative computational models. They are interested in computational chemistry and early-stage discoveries. They utilize parallel molecular dynamics simulations to reveal opportunities within difficult or emerging drug targets, which are the basic drivers of disease. Their initial drug discovery partnerships apply to therapeutic areas that range from cancer to IBD.
The long term strategy for Redesign Science Inc is to hire engineers to scale and automate its technology platform, while also financing its ongoing operations including their cloud computing. The platform is a proprietary platform that performs at an atomic level and has interactions with hundreds of millions of candidate small molecules.
